English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background This study evaluated AXDX (uses FISH/real-time microscopy to obtain ID/AST direct from +BC in <7h) for accuracy against reference mass spectrometry (MS, VITEK® MS, bioMérieux) and broth microdilution (BMD), respectively. AXDX TAT was timed against current reporting for ID using MS and VITEK®2 (VT2, bioMérieux) for AST (VT2 data not presented). Methods Blood from 173 semi-consecutive +BC tested in BacT/Alert® (bioMérieux) with GNB on Gram were tested in AXDX. Susceptible/intermediate/resistant (S/I/R) interpretations were as per CLSI-M100-S27 for cefazolin (CFZ), ceftriaxone (CRO), ceftazidime (CAZ), piperacillin/tazobactam (TZP), ertapenem (ETP), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GM), tobramycin (TOB), and amikacin (AN). ID and AST results were combined across GNB-genera for assessment as per Cumitech 31A for ≥90% agreements [identificatoin, essential (EA); categorical (CA)] and errors [very major (VME) <3%; combined major/minor (ME/mE) <7%]. Results 142 (82.1%) AXDX results were evaluable (ID-agreed/AST-reported) for 78 Escherichia coli, 27 Klebsiella species, 17 Pseudomonas aeruginosa, 5 Enterobacter cloacae, 8 Serratia marcescens, 3 Proteus mirabilis, 2 Acinetobacter baumannii and 2 Citrobacter freundii as seen tabulated below. Limits were exceeded for underlined values but 95% confidence intervals (CI) overlapped acceptable limits except in values marked with asterisks [EA (CAZ: 68.7–82.7), ME/mE (CFZ: 5.1–16.8; CAZ: 10–21.9; TZP: 9.2–20.8)]. VME were not evaluable (NE) for TZP, ETP, MEM, or AN due to insufficient numbers of GNB resistant to these agents. ID/AST TAT means (ranges) for AXDX were 1:21h (1:19–1:24h)/6:38h (6:30–6:59h) conmpared to MS/VT2 of 8:49h (2:49–76:48h)/38:23h (19:44–64:22h), respectively; paired t-tests, P < 0.0001/P < 0.0001; difference of means: 8:17h (95% CI:6:55–9:38h)/28:41h (95% CI:26:53–30:29h)]. Conclusion These data suggest AXDX will significantly reduce ID/AST TAT in GNB bacteremia (ID: 8:49h to 1:21h; AST: 38:23h to 6:38h) with potential to significantly improve patient outcomes. Acceptable accuracy was achieved for ID and AST for most agents. A limitation was the lack of GNB causing bacteremia with resistance to AN, TZP, ETP or MEM in during evaluation. Disclosures B. M. Willey, Mount Sinai Hospital: Investigator, Educational support S. M. Poutanen, Accelerate Diagnostics: Research Contractor and Scientific Advisor, Consulting fee and Research support

open forum infectious diseases

Prospective Evaluation of Accelerate Pheno™ System (AXDX) Version 1.1 for Reducing Turn-Around-Time (TAT) in Identification/Antimicrobial Susceptibility Testing (ID/AST) of Gram-Negative Bacilli (GNB) from Positive Blood Cultures (+BC) using AXDX PhenoTest™ BC Kits